Agilent Technologies, Inc. (A) EV/FCF Ratio: 30.59x
Is Agilent Technologies, Inc.’s EV/FCF ratio high or low?
Agilent Technologies, Inc.'s EV/FCF ratio of 30.59x is in line with its 5-year average of 33.45x, around the middle of its 5-year range (22.05x–48.11x).
As of Monday, June 15, 2026. 11.61% below its 12-month average of 34.61x.
A EV/FCF Ratio Chart
A Average EV/FCF Ratio Chart
A Current vs Average EV/FCF Ratio Chart
A EV/FCF Ratio Metrics
EV/FCF RATIO
30.59x
EV/FCF RATIO AVG TTM
34.61x
EV/FCF RATIO AVG 3Y
30.02x
EV/FCF RATIO AVG 5Y
33.45x
EV/FCF RATIO AVG 10Y
32.29x
EV/FCF RATIO AVG 15Y
27.38x
EV/FCF RATIO AVG 20Y
24.71x
CURRENT VS TTM AVG
-11.61%
CURRENT VS 3Y AVG
+1.89%
CURRENT VS 5Y AVG
-8.56%
CURRENT VS 10Y AVG
-5.25%
CURRENT VS 15Y AVG
+11.72%
CURRENT VS 20Y AVG
+23.79%
A Competitors' EV/FCF Ratio
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agilent Technologies, Inc. (A) | $36.67B | 30.59x | 34.61x | 30.02x | 33.45x |
| Zoetis Inc. (ZTS)vs › | $33.36B | 19.15x | 28.04x | 41.96x | 48.22x |
| Centene Corporation (CNC)vs › | $32.19B | 4.32x | 9.55x | 24.73x | 19.03x |
| Medline Inc. (MDLN)vs › | $30.96B | 26.63x | 27.74x | 27.74x | 27.74x |
| IQVIA Holdings Inc. (IQV)vs › | $30.29B | 17.65x | 19.84x | 27.23x | 27.81x |
| Biogen Inc. (BIIB)vs › | $29.53B | 12.53x | 12.73x | 21.62x | 21.16x |
| IDEXX Laboratories, Inc. (IDXX)vs › | $44.24B | 42.75x | 56.28x | 56.87x | 65.95x |
| DexCom, Inc. (DXCM)vs › | $29.08B | 20.94x | 37.12x | 66.70x | 181.36x |
| Humana Inc. (HUM)vs › | $45.53B | 43.08x | 33.75x | 21.63x | 31.66x |
| Veeva Systems Inc. (VEEV)vs › | $25.92B | 15.02x | 28.59x | 32.68x | 38.09x |
Cash Flow Valuation Comparison
EV/FCF
30.6x
P/FCF
29.4x
FCF Yield
3.41%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
- EV/FCF accounts for debt and cash through enterprise value
- P/FCF only considers equity value
- EV/FCF can be compared across companies with different debt levels
- Both measure how the market values cash generation
Agilent Technologies, Inc. EV/FCF Ratio Formula & Definition
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Agilent Technologies, Inc. EV/FCF Ratio FAQ
- What is the EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The EV/FCF ratio for A stock is 30.59x.
- Is Agilent Technologies, Inc.'s EV/FCF ratio high or low?
- Agilent Technologies, Inc.'s EV/FCF ratio of 30.59x is in line with its 5-year average of 33.45x, around the middle of its 5-year range (22.05x–48.11x).
- What is the TTM average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The TTM average EV/FCF ratio for A stock is 34.61x.
- What is the 3Y average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The 3Y average EV/FCF ratio for A stock is 30.02x.
- What is the 5Y average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The 5Y average EV/FCF ratio for A stock is 33.45x.
- What is the 10Y average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The 10Y average EV/FCF ratio for A stock is 32.29x.
- What is the 15Y average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The 15Y average EV/FCF ratio for A stock is 27.38x.
- What is the 20Y average EV/FCF ratio for Agilent Technologies, Inc. (A)?
- The 20Y average EV/FCF ratio for A stock is 24.71x.
Agilent Technologies, Inc. EV/FCF Ratio History
| DATE | EV/FCF RATIO |
|---|---|
| 2026-06-12 | 30.59x |
| 2026-06-11 | 30.53x |
| 2026-06-10 | 30.99x |
| 2026-06-09 | 31.87x |
| 2026-06-08 | 31.24x |
| 2026-06-05 | 31.86x |
| 2026-06-04 | 32.52x |
| 2026-06-03 | 32.30x |
| 2026-06-02 | 31.77x |
| 2026-06-01 | 31.98x |
| 2026-05-29 | 40.37x |
| 2026-05-28 | 40.33x |
| 2026-05-27 | 34.74x |
| 2026-05-26 | 34.52x |
| 2026-05-22 | 34.49x |
| 2026-05-21 | 34.44x |
| 2026-05-20 | 34.15x |
| 2026-05-19 | 33.23x |
| 2026-05-18 | 33.67x |
| 2026-05-15 | 33.55x |
| 2026-05-14 | 34.00x |
| 2026-05-13 | 33.85x |
| 2026-05-12 | 33.90x |
| 2026-05-11 | 33.49x |
| 2026-05-08 | 34.67x |
| 2026-05-07 | 35.54x |
| 2026-05-06 | 35.27x |
| 2026-05-05 | 35.22x |
| 2026-05-04 | 33.69x |
| 2026-05-01 | 34.36x |
| 2026-04-30 | 34.65x |
| 2026-04-29 | 33.44x |
| 2026-04-28 | 34.46x |
| 2026-04-27 | 34.67x |
| 2026-04-24 | 34.65x |
| 2026-04-23 | 34.33x |
| 2026-04-22 | 36.06x |
| 2026-04-21 | 36.53x |
| 2026-04-20 | 36.20x |
| 2026-04-17 | 36.46x |
| 2026-04-16 | 35.43x |
| 2026-04-15 | 35.86x |
| 2026-04-14 | 36.04x |
| 2026-04-13 | 35.21x |
| 2026-04-10 | 34.51x |
| 2026-04-09 | 34.61x |
| 2026-04-08 | 35.05x |
| 2026-04-07 | 34.18x |
| 2026-04-06 | 34.45x |
| 2026-04-02 | 34.63x |
| 2026-04-01 | 34.37x |
| 2026-03-31 | 34.21x |
| 2026-03-30 | 33.64x |
| 2026-03-27 | 33.14x |
| 2026-03-26 | 34.06x |
| 2026-03-25 | 33.92x |
| 2026-03-24 | 34.27x |
| 2026-03-23 | 33.65x |
| 2026-03-20 | 33.44x |
| 2026-03-19 | 33.57x |
| 2026-03-18 | 33.50x |
| 2026-03-17 | 33.85x |
| 2026-03-16 | 33.59x |
| 2026-03-13 | 33.50x |
| 2026-03-12 | 33.53x |
| 2026-03-11 | 34.62x |
| 2026-03-10 | 34.62x |
| 2026-03-09 | 34.97x |
| 2026-03-06 | 34.52x |
| 2026-03-05 | 35.39x |
| 2026-03-04 | 36.08x |
| 2026-03-03 | 35.65x |
| 2026-03-02 | 30.49x |
| 2026-02-27 | 31.28x |
| 2026-02-26 | 31.18x |
| 2026-02-25 | 32.11x |
| 2026-02-24 | 32.03x |
| 2026-02-23 | 31.98x |
| 2026-02-20 | 31.66x |
| 2026-02-19 | 32.50x |
| 2026-02-18 | 32.65x |
| 2026-02-17 | 31.90x |
| 2026-02-13 | 32.37x |
| 2026-02-12 | 32.14x |
| 2026-02-11 | 33.14x |
| 2026-02-10 | 33.16x |
| 2026-02-09 | 32.79x |
| 2026-02-06 | 33.30x |
| 2026-02-05 | 33.32x |
| 2026-02-04 | 34.14x |
| 2026-02-03 | 33.93x |
| 2026-02-02 | 34.74x |
| 2026-01-30 | 34.36x |
| 2026-01-29 | 34.21x |
| 2026-01-28 | 34.36x |
| 2026-01-27 | 34.87x |
| 2026-01-26 | 34.80x |
| 2026-01-23 | 34.65x |
| 2026-01-22 | 35.53x |
| 2026-01-21 | 35.82x |
| 2026-01-20 | 34.84x |
| 2026-01-16 | 35.78x |
| 2026-01-15 | 37.06x |
| 2026-01-14 | 37.33x |
| 2026-01-13 | 37.43x |
| 2026-01-12 | 37.84x |
| 2026-01-09 | 37.97x |
| 2026-01-08 | 37.29x |
| 2026-01-07 | 37.80x |
| 2026-01-06 | 37.75x |
| 2026-01-05 | 36.59x |
| 2026-01-02 | 35.37x |
| 2025-12-31 | 34.90x |
| 2025-12-30 | 35.29x |
| 2025-12-29 | 35.36x |
| 2025-12-26 | 35.48x |
| 2025-12-24 | 35.46x |
| 2025-12-23 | 35.47x |
| 2025-12-22 | 35.51x |
| 2025-12-19 | 35.19x |
| 2025-12-18 | 37.58x |
| 2025-12-17 | 37.52x |
| 2025-12-16 | 38.18x |
| 2025-12-15 | 38.55x |
| 2025-12-12 | 38.31x |
| 2025-12-11 | 39.15x |
| 2025-12-10 | 39.30x |
| 2025-12-09 | 38.56x |
| 2025-12-08 | 39.03x |
| 2025-12-05 | 39.83x |
| 2025-12-04 | 40.57x |
| 2025-12-03 | 40.82x |
| 2025-12-02 | 40.70x |
| 2025-12-01 | 41.04x |
| 2025-11-28 | 41.93x |
| 2025-11-26 | 42.16x |
| 2025-11-25 | 42.90x |
| 2025-11-24 | 41.96x |
| 2025-11-21 | 41.34x |
| 2025-11-20 | 39.72x |
| 2025-11-19 | 39.55x |
| 2025-11-18 | 39.40x |
| 2025-11-17 | 39.58x |
| 2025-11-14 | 40.18x |
| 2025-11-13 | 40.20x |
| 2025-11-12 | 41.41x |
| 2025-11-11 | 40.86x |
| 2025-11-10 | 40.06x |
| 2025-11-07 | 40.16x |
| 2025-11-06 | 40.36x |
| 2025-11-05 | 40.17x |
| 2025-11-04 | 39.99x |
| 2025-11-03 | 39.62x |
| 2025-10-31 | 40.06x |
| 2025-10-30 | 39.28x |
| 2025-10-29 | 39.23x |
| 2025-10-28 | 39.93x |
| 2025-10-27 | 40.12x |
| 2025-10-24 | 40.50x |
| 2025-10-23 | 40.35x |
| 2025-10-22 | 39.93x |
| 2025-10-21 | 39.88x |
| 2025-10-20 | 39.18x |
| 2025-10-17 | 38.90x |
| 2025-10-16 | 38.68x |
| 2025-10-15 | 38.30x |
| 2025-10-14 | 37.88x |
| 2025-10-13 | 37.93x |
| 2025-10-10 | 37.51x |
| 2025-10-09 | 38.42x |
| 2025-10-08 | 38.61x |
| 2025-10-07 | 38.02x |
| 2025-10-06 | 38.82x |
| 2025-10-03 | 38.82x |
| 2025-10-02 | 38.05x |
| 2025-10-01 | 38.02x |
| 2025-09-30 | 35.34x |
| 2025-09-29 | 34.14x |
| 2025-09-26 | 34.04x |
| 2025-09-25 | 33.65x |
| 2025-09-24 | 34.30x |
| 2025-09-23 | 34.71x |
| 2025-09-22 | 34.81x |
| 2025-09-19 | 34.81x |
| 2025-09-18 | 35.15x |
| 2025-09-17 | 34.92x |
| 2025-09-16 | 35.04x |
| 2025-09-15 | 34.63x |
| 2025-09-12 | 34.00x |
| 2025-09-11 | 34.92x |
| 2025-09-10 | 34.24x |
| 2025-09-09 | 34.79x |
| 2025-09-08 | 35.29x |
| 2025-09-05 | 35.45x |
| 2025-09-04 | 35.38x |
| 2025-09-03 | 34.52x |
| 2025-09-02 | 34.52x |
| 2025-08-29 | 34.64x |
| 2025-08-28 | 31.64x |
| 2025-08-27 | 30.14x |
| 2025-08-26 | 30.05x |
| 2025-08-25 | 30.25x |
| 2025-08-22 | 30.84x |
| 2025-08-21 | 29.77x |
| 2025-08-20 | 30.24x |
| 2025-08-19 | 30.48x |
| 2025-08-18 | 30.01x |
| 2025-08-15 | 30.26x |
| 2025-08-14 | 30.18x |
| 2025-08-13 | 30.52x |
| 2025-08-12 | 29.81x |
| 2025-08-11 | 29.05x |
| 2025-08-08 | 29.16x |
| 2025-08-07 | 29.01x |
| 2025-08-06 | 28.83x |
| 2025-08-05 | 29.23x |
| 2025-08-04 | 29.22x |
| 2025-08-01 | 28.90x |
| 2025-07-31 | 29.21x |
| 2025-07-30 | 29.99x |
| 2025-07-29 | 30.41x |
| 2025-07-28 | 30.34x |
| 2025-07-25 | 30.50x |
| 2025-07-24 | 30.54x |
| 2025-07-23 | 30.33x |
| 2025-07-22 | 29.54x |
| 2025-07-21 | 28.55x |
| 2025-07-18 | 29.01x |
| 2025-07-17 | 29.58x |
| 2025-07-16 | 28.88x |
| 2025-07-15 | 28.76x |
| 2025-07-14 | 30.47x |
| 2025-07-11 | 31.24x |
| 2025-07-10 | 31.45x |
| 2025-07-09 | 30.76x |
| 2025-07-08 | 30.70x |
| 2025-07-07 | 30.27x |
| 2025-07-03 | 30.78x |
| 2025-07-02 | 30.61x |
| 2025-07-01 | 30.56x |
| 2025-06-30 | 29.98x |
| 2025-06-27 | 30.25x |
| 2025-06-26 | 30.31x |
| 2025-06-25 | 30.12x |
| 2025-06-24 | 29.89x |
| 2025-06-23 | 29.53x |
| 2025-06-20 | 29.39x |
| 2025-06-18 | 29.38x |
| 2025-06-17 | 29.52x |
| 2025-06-16 | 30.22x |
| 2025-06-13 | 29.75x |
| 2025-06-12 | 30.19x |
| 2025-06-11 | 30.39x |
| 2025-06-10 | 30.58x |
| 2025-06-09 | 29.67x |
| 2025-06-06 | 29.45x |
| 2025-06-05 | 29.00x |
| 2025-06-04 | 29.24x |
| 2025-06-03 | 28.72x |
| 2025-06-02 | 28.31x |
Showing the most recent 260 of 5,033 data points. The chart above shows the full history.
Related Metrics
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell